Compare Stocks: SCNX, CLNN, GRCE, and RYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$4.54 +4.4%	$4.64	$3.25 ▼ $13.50	$56.53M	0.95	138,226 shs	108,882 shs
GRCE Grace Therapeutics	$2.10 -0.5%	$2.20	$1.79 ▼ $5.18	$44.39M	0.44	138,982 shs	109,941 shs
RYM RYTHM	$23.58 +5.2%	$22.00	$14.00 ▼ $53.65	$48.83M	9.44	13,988 shs	5,958 shs
SCNX Scienture	$0.30 -2.8%	$0.39	$0.24 ▼ $2.60	$12.87M	3.25	686,773 shs	409,696 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	+4.37%	+38.41%	+5.09%	-21.32%	-28.95%
GRCE Grace Therapeutics	-0.47%	-8.30%	-4.55%	-12.13%	-32.26%
RYM RYTHM	+5.20%	+7.26%	+3.63%	-7.04%	+2,357,499,900.00%
SCNX Scienture	-2.81%	-10.09%	-32.24%	-20.21%	-65.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLNN Clene	$4.54 +4.4%	$4.64	$3.25 ▼ $13.50	$56.53M	0.95	138,226 shs	108,882 shs
GRCE Grace Therapeutics	$2.10 -0.5%	$2.20	$1.79 ▼ $5.18	$44.39M	0.44	138,982 shs	109,941 shs
RYM RYTHM	$23.58 +5.2%	$22.00	$14.00 ▼ $53.65	$48.83M	9.44	13,988 shs	5,958 shs
SCNX Scienture	$0.30 -2.8%	$0.39	$0.24 ▼ $2.60	$12.87M	3.25	686,773 shs	409,696 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLNN Clene	+4.37%	+38.41%	+5.09%	-21.32%	-28.95%
GRCE Grace Therapeutics	-0.47%	-8.30%	-4.55%	-12.13%	-32.26%
RYM RYTHM	+5.20%	+7.26%	+3.63%	-7.04%	+2,357,499,900.00%
SCNX Scienture	-2.81%	-10.09%	-32.24%	-20.21%	-65.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLNN Clene	2.71	Moderate Buy	$34.00	648.90% Upside
GRCE Grace Therapeutics	2.00	Hold	$6.00	185.71% Upside
RYM RYTHM	1.00	Sell	N/A	N/A
SCNX Scienture	2.00	Hold	$1.50	392.29% Upside

Current Analyst Ratings Breakdown

Latest SCNX, CLNN, GRCE, and RYM Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/10/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	CLNN Clene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	RYM RYTHM	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/3/2026	GRCE Grace Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/30/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	GRCE Grace Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	CLNN Clene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	SCNX Scienture	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLNN Clene	$200K	294.87	N/A	N/A	($1.62) per share	-2.80
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	$3.99 per share	N/A
RYM RYTHM	$17.28M	2.97	N/A	N/A	$6.06 per share	3.89
SCNX Scienture	$430K	29.10	N/A	N/A	$1.73 per share	0.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLNN Clene	-$26.17M	-$3.50	N/A	N/A	N/A	-20,063.96%	N/A	-137.04%	11/12/2026 (Estimated)
GRCE Grace Therapeutics	-$7.79M	-$1.18	N/A	N/A	N/A	N/A	-36.11%	-34.39%	11/12/2026 (Estimated)
RYM RYTHM	-$33.26M	-$10.53	N/A	N/A	N/A	-6.20%	-12.57%	-2.60%	N/A
SCNX Scienture	-$41.51M	-$2.10	N/A	N/A	N/A	N/A	-53.51%	-42.47%	11/12/2026 (Estimated)

Latest SCNX, CLNN, GRCE, and RYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CLNN Clene	-$0.3680	-$1.08	-$0.7120	-$1.08	$0.06 million	$0.09 million
8/14/2026	Q1 2027	GRCE Grace Therapeutics	-$0.1293	-$0.91	-$0.7807	-$0.91	$0.40 million	N/A
8/13/2026	Q2 2026	SCNX Scienture	-$0.09	-$0.07	+$0.02	-$0.07	$1.96 million	$0.34 million
8/4/2026	Q2 2026	RYM RYTHM	N/A	$0.09	N/A	$0.09	N/A	$23.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLNN Clene	N/A	N/A	N/A	N/A	N/A
GRCE Grace Therapeutics	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	N/A	N/A	N/A	N/A	N/A
SCNX Scienture	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLNN Clene	N/A	3.07	3.07
GRCE Grace Therapeutics	N/A	11.47	11.47
RYM RYTHM	N/A	0.59	0.56
SCNX Scienture	0.15	3.04	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLNN Clene	23.28%
GRCE Grace Therapeutics	6.08%
RYM RYTHM	5.98%
SCNX Scienture	5.68%

Insider Ownership

Company	Insider Ownership
CLNN Clene	28.30%
GRCE Grace Therapeutics	10.84%
RYM RYTHM	3.48%
SCNX Scienture	21.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLNN Clene	79	12.99 million	9.32 million	No Data
GRCE Grace Therapeutics	5	21.04 million	18.76 million	N/A
RYM RYTHM	141	2.18 million	2.10 million	N/A
SCNX Scienture	9	41.06 million	32.28 million	N/A

SCNX, CLNN, GRCE, and RYM Headlines

Recent News About These Companies

Tvardi Therapeutics (NASDAQ:TVRD) & Scienture (NASDAQ:SCNX) Head-To-Head Survey

September 20 at 3:58 AM | americanbankingnews.com

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

September 9, 2026 | globenewswire.com

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses

August 14, 2026 | quiverquant.comQ

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

August 14, 2026 | globenewswire.com

Scienture Holdings Stock Price History

August 12, 2026 | investing.com

Scienture launches Rezenopy as second FDA-approved commercial product

August 12, 2026 | msn.com

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

August 12, 2026 | globenewswire.com

Scienture Holdings纳洛酮鼻喷雾剂7月将向美批发商发货

July 28, 2026 | finance.sina.com.cnF

Scienture Holdings stock jumps over 20% pre-market: Here's why

July 10, 2026 | msn.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | finance.yahoo.com

SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers

July 9, 2026 | globenewswire.com

SCNX Share News Today

July 4, 2026 | uk.investing.com

Scienture Holdings (SCNX) Stock Forecast & Price Target

June 25, 2026 | investing.com

Scienture Holdings Stock Short Interest Report | NASDAQ:SCNX | Benzinga

June 24, 2026 | benzinga.com

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

June 18, 2026 | globenewswire.com

Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX)

June 17, 2026 | theglobeandmail.com

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

June 9, 2026 | globenewswire.com

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

June 4, 2026 | accessnewswire.comA

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

June 2, 2026 | globenewswire.com

Scienture Holdings Announces CFO Resignation, Names Interim Successor

May 29, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, CLNN, GRCE, and RYM Company Descriptions

Clene NASDAQ:CLNN

$4.54 +0.19 (+4.37%)

As of 09/21/2026 04:00 PM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Grace Therapeutics NASDAQ:GRCE

$2.10 -0.01 (-0.47%)

As of 09/21/2026 04:00 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

RYTHM NASDAQ:RYM

$23.58 +1.17 (+5.20%)

As of 09/21/2026 03:23 PM Eastern

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

Scienture NASDAQ:SCNX

$0.30 -0.01 (-2.81%)

As of 09/21/2026 04:00 PM Eastern

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, CLNN, GRCE, and RYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, CLNN, GRCE, and RYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, CLNN, GRCE, and RYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, CLNN, GRCE, and RYM Company Descriptions

Clene NASDAQ:CLNN

Grace Therapeutics NASDAQ:GRCE

RYTHM NASDAQ:RYM

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCNX, CLNN, GRCE, and RYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCNX, CLNN, GRCE, and RYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCNX, CLNN, GRCE, and RYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNX, CLNN, GRCE, and RYM Company Descriptions

Clene NASDAQ:CLNN

Grace Therapeutics NASDAQ:GRCE

RYTHM NASDAQ:RYM

Scienture NASDAQ:SCNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools